Fierce Biotech February 9, 2024
Max Bayer

Kyverna CEO Peter Maag, Ph.D., was unequivocal when asked how it feels to be one of biotech’s torchbearers for autoimmune-focused cell therapies.

“I think we’re in the next phase of medicine; I think it’s the next 30 years,” he said, comparing the burgeoning modality to monoclonal antibodies.

He and Kyverna just closed a $319 million IPO to prove just that, adding more financial caffeine to an awakening public marketplace that so far in 2024 seems significantly more amenable than in the prior two years.

Kyverna’s shares closed at $30 apiece on Thursday evening, more than $8 higher than the $22 price point that the company launched onto Nasdaq with earlier in the day.

The biotech’s public-market plans...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Pharma / Biotech
Drugmakers counter HHS' first offers in Medicare price talks
Pfizer stops buildout of $350M Seagen plant, leaving 120 workers' roles in question
ARPA-H behind on duplicative research efforts, GAO says
Science Continues To Outpace Commercialization Of Cell And Gene Therapies
Opinion: Missing data is making it difficult for the pharmaceutical industry to help LGBTQ+ people

Share This Article